Possibility of diagnosis and treatment of thrombotic complications in primary mediastinal B-cell lymphoma


Aim. Efficacy of the treatment of primary mediastinal B-cell lymphosarcoma depends to a great extent on early diagnosis and treatment policy. In this study we evaluated possibilities of diagnosis and treatment of thrombotic complications of primary mediastinal B-cell lymphosarcoma (PMBL). Material and methods. 61 patients were examined using roentgenography, computed tomography, chest ultrasound investigation,coagulogram, allelle specific polymerase chain reaction, ultrasound investigation of the jugular, subclavian, brachial veins, vena cava superior to detect mutation of genes II, Vfactors and methylentetrahydrofolatereductase.
Results. In 7 cases prechemotherapy examination detected thrombosis of the internal jugular and subclavian veins. In 4 of 7 cases there was a combined thrombosis of the left internal jugular and subclavian veins, in 3 cases one the vessels was affected with thrombosis. In 2 cases, in the course of polychemotherapy, there was recurrent thrombosis and development of pulmonary artery thromboembolism (PATE). In progression of the disease there was thrombosis of the left subclavian vein (1 case) and PA ТЕ (a case). Coagulologically, hypercoagulation syndrome signs were registered. 5 patients with PMBL complicated by thromboses showed gene mutations.
Conclusion. In PMBL there is a tendency to formation of venous thrombosis and development of PATE. This is explained by tumor process and hereditary factors of thrombogenicity. Therefore, specific antitumor treatment should include anticoagulation theerapy.


  1. Баркаган 3. С. Критические факторы тромбогенности и современные методы патогенетической профилактики и лечения тромбоэмболии. Сиб. мед. журн. 1996; 2: 60-62.
  2. Баркаган 3. С. Нарушение гемостаза у онкогематологических больных. В кн.: Волкова М. А. (ред.) Клиническая онкогематология. М.: Медицина; 2001. 469-478.
  3. Баркаган 3. С. Патогенез и терапия нарушений гемостаза у онкологических больных. В кн.: Личиницер М. Р., Арго М. (ред.) Поддерживающая терапия у онкологических больных. Европейская школа по онкологии. М.: Медицина; 1996. 217-224.
  4. Баркаган 3. С. Патогенез и терапия нарушений гемостаза у онкологических больных. Тер. арх. 1997; 7: 65-67.
  5. Gale A. J., Gordon S. G. Update on tumor cell procoagulant factors. Acta Haematol. 2001; 106: 25-32.
  6. Rickles F. R. Relationship of blood clotting and tumor angiogenesis. Haemostasis 2001; 31 (suppl. 1): 16-20.
  7. Rickles F. R., Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb. Res. 2001; 102 (6): 215-224.
  8. Contrino J., Goralnik S., Qi J. et al. Fibrin induction of tissue factor expression in human vascular endothelial cells. Circulation 1997; 96: 605-613.
  9. Qui J., Kreutzer D. L. Fibrin activation of vascular endothelial cells: induction of tissue factor expression in human vascular endothelial cells. J. Immunol. 1995; 155: 867-876.
  10. Hara H., Steiner M., Baldini M. G. Characterization of the platelet-aggregating activity of tumor cells. Cancer Res. 1980; 40: 1217-1222.
  11. Shoji M., Hancock W. W., Abe K. et al. Activation of coagulation and angiogenesis in cancer. Am. J. Pathol. 1998; 152: 399-411.
  12. Шмелева В. М. Гипергомоцистеинемия и тромбоз. Тромбоз, гемостаз и реол. 2000; 4: 26-29.
  13. Bick R. L. Coagulation abnormalities in malignancy: A review. Semin. Thromb. Hemost. 1922; 338: 1169-1173.
  14. Colman R. W., Rubin R. N. Disseminated intravascular coagulation due to malignancy. Semin. Oncol. 1990; 17: 172-176.
  15. Джумабаева Б. Т., Кременецкая А. М., Шавлохов В. С. и др. Сравнительный анализ эффективности терапии первичной медиастинальной В-клеточной лимфосаркомы программами 1.2 и 3 генерации. Гематол. и трансфузиол. 2003; 4: 11-13.
  16. Шулутко Е. М., Городецкий В. М., Гетман Л. Н., Васильев С. А. Тромботические осложнения катетеризации центральных вен. В кн.: Материалы II Конференции ассоциации флебологов России. М.: Медицина; 1999. 114- 115.

Copyright (c) 2004 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies